Loading...
XNAS
IMAB
Market cap75mUSD
Jul 14, Last price  
2.14USD
1D
0.47%
1Q
135.89%
IPO
-84.49%
Name

I-Mab

Chart & Performance

D1W1MN
P/E
—
P/S
45.30
EPS
—
Div Yield, %
—
Shrs. gr., 5y
96.53%
Rev. gr., 5y
-12.46%
Revenues
28m
P
11,556,00053,781,00030,000,0001,542,668,00088,026,000-221,563,00027,644,000
Net income
-1.47b
L-41.54%
-298,240,000-402,833,000-1,485,001,000470,915,000-2,331,541,000-2,507,317,000-1,465,694,000
CFO
-53m
L-95.96%
-252,157,000-280,705,000-867,982,000433,558,000-973,093,000-1,102,805,000-1,304,950,000-52,669,000
Earnings
Aug 26, 2025

Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
URL
https://www.i-mabbiopharma.com/
IPO date
Jan 17, 2020
Employees
378
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
27,644
-112.48%
(221,563)
-351.70%
Cost of revenue
178,267
1,747,904
Unusual Expense (Income)
NOPBT
(150,623)
(1,969,467)
NOPBT Margin
888.90%
Operating Taxes
697
Tax Rate
NOPAT
(150,623)
(1,970,164)
Net income
(1,465,694)
-41.54%
(2,507,317)
7.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
(335)
(21,249)
BB yield
14.17%
Debt
Debt current
816
7,316
42,917
Long-term debt
6,948
9,605
88,099
Deferred revenue
267,878
Other long-term liabilities
479,738
105,650
Net debt
(196,458)
(2,274,312)
(3,349,268)
Cash flow
Cash from operating activities
(52,669)
(1,304,950)
(1,102,805)
CAPEX
(48)
(11,351)
(45,830)
Cash from investing activities
(136,015)
102,515
458,382
Cash from financing activities
(335)
7,572
42,357
FCF
7,898
(38,353)
(1,579,442)
Balance
Cash
173,398
2,289,529
3,449,434
Long term investments
30,824
1,704
30,850
Excess cash
204,222
2,289,851
3,491,362
Stockholders' equity
(1,252,636)
(8,285,745)
(6,549,800)
Invested Capital
1,457,678
10,494,214
10,006,640
ROIC
ROCE
EV
Common stock shares outstanding
83,228
82,516
Price
0.37
-55.26%
0.83
-54.55%
1.82
-91.18%
Market cap
68,753
-54.15%
149,964
-90.42%
EV
(2,205,559)
(3,199,304)
EBITDA
978
(143,187)
(1,905,651)
EV/EBITDA
15.40
1.68
Interest
102
Interest/NOPBT